GPBAR1 and Obesity: Although definitive clinical studies are missing in this respect, the GPBAR-1 agonists might become an attractive therapeutic option for the treatment of nonalcoholic steatohepatitis (NASH), especially in patients with diabetes and obesity [43,56,91,92].